Esperion Therapeutics (ESPR): Evaluating Valuation After $75 Million Equity Raise and Recent Share Price Volatility
Esperion Therapeutics (ESPR) just completed a $75 million follow-on equity offering, issuing 30 million shares at $2.50 each. This capital raise comes at a key time for the company and could affect its balance sheet and future strategies.
See our latest analysis for Esperion Therapeutics.
Following this equity raise, Esperion Therapeutics has seen volatility build, with the share price dropping 16.8% in a day after the announcement but still holding a remarkable 107% 90-day return and a 33% total shareholder return over the year. Short-term momentum is strong; however, the long-term track record remains challenging, reflecting the high-stakes biotech landscape.
If this kind of turnaround caught your attention, tap into the next wave of…
